You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 391 Development of the comprehensive score for financial toxicity (COST) tool and assessment of financial toxicity in patients with gynecologic cancer in japan

Article Text

Article menu

Download PDFPDF

E-Poster viewings
Trials in Progress
IGCS19-0146
391 Development of the comprehensive score for financial toxicity (COST) tool and assessment of financial toxicity in patients with gynecologic cancer in japan
Free
  1. Y Kajimoto1,2,
  2. K Honda3,
  3. K Fujiwara4,
  4. M Mizuno5,
  5. T Nishimura6,
  6. H Fujiwara7,
  7. T Koyanagi7,
  8. I Kohara8,
  9. S Tamaki9 and
  10. A Igarashi1,10
  1. 1The University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan
  2. 2Kanagawa Institute of Industrial Science and Technology, Global Health Research Coordinating Center, Kawasaki, Japan
  3. 3Aichi Cancer Center Hospital, Department of Clinical Oncology, Nagoya, Japan
  4. 4Saitama medical university International medical Center, Department of Gynecologic Oncology, Hidaka, Japan
  5. 5Aichi Cancer Center Hospital, Department of Gynecologic Oncology, Nagoya, Japan
  6. 6Gunma University Hospital, Department of Obstetrics and Gynecology, Maebashi, Japan
  7. 7Jichi Medical University, Department of Obstetrics and Gynecology, Shimotsuke, Japan
  8. 8Jichi Medical University, School of Nursing, Shimotsuke, Japan
  9. 9Saitama medical university International medical Center, Nursing department, Hidaka, Japan
  10. 10Yokohama City University School of Medicine, Unit of Public Health and Preventive Medicine, Yokohama, Japan

Abstract

Objectives As new medical technology develops, medical costs increase. When high medical costs affect the patient as a toxicity, it is called financial toxicity (FT). In Japan, all patients are covered by the public health insurance system, which may alleviate FT. However, previous research using the Japanese version of the ‘‘‘‘‘COmprehensive Score for financial Toxicity (COST)’’’’’ tool, whose score quantifies FT, showed that Japanese patients with cancer had FT. Our objective is to analyze its internal validity and the relationship between the COST score and patient information particularly for patients with ovarian, cervical, or endometrial cancer during chemotherapy. Furthermore, this study aims to clarify the correlation between COST and QOL scores.

Methods We will enroll 147 patients, including 49 patients each with ovarian, cervical, and endometrial cancers, from April 2019 to April 2020. Each patient will have been receiving chemotherapy for more than 2 months at enrollment. Each participant will answer the COST tool, EORTC-QLQ-C30, OV28/CX24/EN24, and EQ-5D-5L at baseline and at the end of chemotherapy. The patients will also complete a questionnaire about employment, assets, income, private insurance, medical payments in the last 2 months, presence of children or family members who need a caregiver, and consultation for medical payment before chemotherapy.

Results This research will clarify the characteristics and longitudinal changes in the COST score in gynecologic cancer patients. The impact of FT on the clinical situation will also be determined.

Conclusions We expect to find that the COST score can be used prospectively to improve QOL in patients with gynecologic cancer.

https://doi.org/10.1136/ijgc-2019-IGCS.391

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.